Positive Interim Ph 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer Announced October 29, 2024
ZL-1310 Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage SCLC October 29, 2024
Positive and Statistically Significant OS and PFS Results for Zepzelca® (lurbinectedin) & Atezolizumab Combo in 1L Maintenance Therapy for ES-SCLC October 22, 2024
TAGRISSO + ORPATHYS demonstrated high, clinically meaningful response rate in NSCLC patients with MET overexpression and/or amplification in SAVANNAH Ph2 trial October 22, 2024
First Patient Dosed in Ph 1/2 Trial of PFL-241/STX-241 in Locally Advanced or Metastatic NSCLC patients October 15, 2024
FDA Approves Perioperative Treatment of Neoadjuvant Opdivo and Chemo Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable NSCLC October 15, 2024
BDTX-1535 program to be advanced into pivotal development based on robust Ph 2 clinical data from EGFRm NSCLC patients October 15, 2024
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC October 15, 2024
US FDA Approves Perioperative Treatment of Neoadjuvant Opdivo and Chemo Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable NSCLC October 8, 2024
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens® October 8, 2024
Preliminary safety data from the Ph 1b portion of the BGBC016 study in 1L NSCLC patients announced October 8, 2024
FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers October 8, 2024
BLA submitted for accelerated approval for Telisotuzumab Vedotin (Teliso-V) in Previously Treated NSCLC with c-Met protein overexpression based on Ph 2 LUMINOSITY trial (M14-239) data October 2, 2024
Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer October 2, 2024
Initial Ph 2 Data of BDTX-1535 in Patients with Recurrent EGFRm NSCLC with Classical, Non-classical, and C797S Resistance Mutations Announced October 1, 2024
KEYTRUDA Receives New Approvals in Japan for perioperative Patients With NSCLC and in Radically Unresectable Urothelial Carcinoma October 1, 2024
Patritumab Deruxtecan Demonstrated Statistically Significant PFS Improvement vs Chemo in Locally Advanced or Metastatic EGFRm NSCLC in HERTHENA-Lung02 Ph 3 Trial September 24, 2024
RYBREVANT® (amivantamab-vmjw) + SOC approved in the US to cut risk of disease progression by more than half in 2L EGFR-mutated advanced NSCLC September 24, 2024
FDA Approves KEYTRUDA + Pemetrexed + Chemo as 1L Treatment for Adult Patients With Unresectable Advanced/Metastatic Malignant Pleural Mesothelioma (MPM) September 24, 2024
TIL-based cNeT program to be discontinued and Ph 1/2a CHIRON and THETIS clinical trials to be closed September 24, 2024
Zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients September 18, 2024
